Showing results (121-130 of 396) with videos related to
Sort By:
Pageof 40
European Journal of Cancer (Oxford, England : 1990)|June 8, 2019
Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF<sup>V600</sup> mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinibKarl Lewis, Axel Hauschild, James Larkin, et al.JAMA Oncology|August 4, 2018
Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical TrialsAxel Hauschild, James Larkin, Antoni Ribas, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 9, 2021
Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805)Wenxin Xu, Mäneka Puligandla, Brian Halbert, et al.Journal of Translational Medicine|August 5, 2020
Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trialsPaolo A Ascierto, Antoni Ribas, James Larkin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2015
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)Keith T Flaherty, Judith B Manola, Michael Pins, et al.Journal of Neurosurgery|January 5, 2008
Effect of decompressive craniectomy on intracranial pressure and cerebrospinal compensation following traumatic brain injuryIvan Timofeev, Marek Czosnyka, Jurgens Nortje, et al.Molecular Cancer Therapeutics|April 26, 2013
CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanomaRoberto A Salas Fragomeni, Hye Won Chung, Yosef Landesman, et al.The Lancet. Oncology|November 20, 2016
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trialsGeorgina V Long, Jean-Jacques Grob, Paul Nathan, et al.Nature Reviews. Drug Discovery|September 7, 2013
Considerations for the successful co-development of targeted cancer therapies and companion diagnosticsJane Fridlyand, Richard M Simon, Jessica C Walrath, et al.Acta Neurochirurgica|September 7, 2019
Indocyanine green fluorescence video angiography reduces vascular injury-related morbidity during micro-neurosurgical clipping of ruptured cerebral aneurysms: a retrospective observational studyTamara Tajsic, James Cullen, Mathew Guilfoyle, et al.Pageof 40